Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cue Biopharma, Inc. (CUE) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company (Commission File Number 001-38327), Cue Biopharma uses SEC reports to communicate financial results, material agreements, leadership changes and other significant corporate events.
Investors researching CUE stock can review Form 10-K annual reports and Form 10-Q quarterly reports for detailed information on collaboration revenue, research and development spending, general and administrative expenses, cash and marketable securities, and risk factors related to the development of its Immuno-STAT® platform and pipeline candidates such as CUE-101, CUE-102, CUE-401 and CUE-501.
Form 8-K current reports are particularly relevant for Cue Biopharma, as they document material events including collaboration and license agreements, public offerings under its Form S-3 shelf registration statement, changes in executive leadership, facility lease amendments and key licensing transactions like the collaboration with ImmunoScape for the CUE-100 series. These filings often reference press releases furnished as exhibits, providing additional context on clinical and business developments.
This page also helps users locate information related to equity compensation and executive arrangements, which are described in employment agreements and separation agreements disclosed in 8-K filings. While Cue Biopharma’s insider transactions would appear in Form 4 filings submitted by individual officers and directors, aggregating these documents alongside periodic reports offers a fuller picture of governance and ownership activity.
Stock Titan enhances access to Cue Biopharma’s SEC filings with AI-powered summaries that explain key points from lengthy documents, highlight notable changes from prior periods and surface items that may be important to shareholders. Real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K and related forms are available promptly, helping users navigate the regulatory record behind CUE stock.
Cue Biopharma reported continued clinical-stage operating losses while taking steps to bolster liquidity through financing and partnerships. The company held $27.5 million of cash and cash equivalents as of June 30, 2025 and reported a net loss of $20.7 million for the six months ended June 30, 2025 (net loss of $8.48 million for the quarter). Accumulated deficit was $362.6 million and weighted average shares outstanding increased to 84.86 million for the six-month period.
The company raised capital through a 2025 public offering that generated $18.0 million net proceeds, modest ATM proceeds during the period, and received a $10.1 million upfront payment from a collaboration and license agreement with Boehringer Ingelheim (BI) that also includes up to approximately $345 million in potential milestones and royalties. Management discloses substantial doubt about the company’s ability to continue as a going concern and notes all Term Loans are due December 1, 2025.
Cue Biopharma, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The press release is included as Exhibit 99.1 to this Current Report and the company states that the information is being "furnished" rather than "filed," so it is not subject to the liability provisions of Section 18 of the Exchange Act and is not incorporated by reference into other filings except by specific reference. The registrant’s common stock trades on the Nasdaq Capital Market under the symbol CUE.